Our Vice President of North American Business Development, Daniel Conlon, will be at the Boston BD conference on September 10. This invitation-only event brings together Biopharma thought leaders to network and explore insights into the business challenges and opportunities facing…
The latest issue of Chemistry Today features a range of interesting contributions in the field of peptide therapeutics, covering drug discovery processes as well as peptide manufacturing and efficient purification methodologies. Elisabetta Bianchi, Director of Peptide Chemistry at IRBM, was…
The essential amino acid tryptophan and the enzymes that cause its degradation influence the regulation of immune, neuronal and intestinal systems. A recent Nature Drug Discovery paper reviewed the potential of tryptophan metabolites as therapeutic targets in a range of…
Despite the fact that less than 20% of the proteome has enzymatic activity, most drug development efforts have so far focused on identifying enzymatic inhibitors. However, targeting a cell’s proteasomal machinery is now considered an effective area of research. As…
19th November 2018, Pomezia, Italy – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
November 5-7, 2018 Copenhagen, Denmark Come meet IRBM’s delegates in Copenhagen to learn more about how IRBM can support your drug discovery efforts. Drop us a line to request a meeting through our contact form or, when open, the PartneringONE…
September 5-6, Boston, USA Our Global VP of Sales and Marketing, Heidi Kingdon-Jones, will join delegates from all over the world at Biopharm America in Boston. To meet with Heidi and learn about IRBM’s capabilities, reach out to us through…
4th September 2018, Pomezia, Italy – IRBM, today announced a new agreement in the peptide therapeutics area with Merck & Co. Inc., Kenilworth NJ USA, known as MSD outside the United States and Canada, continuing their long-standing history of collaboration that began in 2010.
September 2-6, Ljubljana, Slovenia Our delegates, Dr. Jesus Maria Ontoria and Dr. Pier Giorgio Pacifici, will be attending the EFMC International Symposium of Medicinal Chemistry. If you’d like to learn more about what IRBM can do for your projects, or…
IRBM researchers, led by Dr. Edith Monteagudo, have published a novel method to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. Click on the link below to visit the article’s page on ScienceDirect. A liquid chromatography high-resolution…